Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
BenzePrO Creamy Wash
×
Overview
What is BenzePrO Creamy Wash?
BenzePrOTM Creamy Wash is intended for topical administration and contains Benzoyl Peroxide for use in the treatment of acne vulgaris. Benzoyl Peroxide is an oxidizing agent that possesses antibacterial properties and is classified as a keratolytic. Benzoyl Peroxide (C14H10O4) is represented by the following chemical structure:
Each gram of BenzePrOTM Creamy Wash contains 70 mg of Benzoyl Peroxide as microsphere particles (via Curoxyl® 42) in an emulsion based formulation consisting of: aloe, carbomer 940, cetyl alcohol, disodium oleamido MEA-sulfosuccinate, disodium EDTA, glyceryl stearate/PEG-100 stearate, glycerin, green tea, laureth-12, magnesium aluminum silicate, propylene glycol, purified water, sodium coco-sulfate, sodium lauroamphoacetate, xanthan gum.
What does BenzePrO Creamy Wash look like?
What are the available doses of BenzePrO Creamy Wash?
Sorry No records found.
What should I talk to my health care provider before I take BenzePrO Creamy Wash?
Sorry No records found
How should I use BenzePrO Creamy Wash?
BenzePrOTM Creamy Wash is indicated for the topical treatment of acne vulgaris.
BenzePrOTM Creamy Wash: Apply to affected areas once or twice a day, or as directed by your physician. Wet skin and liberally apply to areas to be cleansed. Massage gently into skin for 10-20 seconds, working into a full lather. Rinse thoroughly and pat dry. If excessive drying occurs, control by rinsing off cleanser sooner or using less often.
What interacts with BenzePrO Creamy Wash?
Sorry No Records found
What are the warnings of BenzePrO Creamy Wash?
Sorry No Records found
What are the precautions of BenzePrO Creamy Wash?
Sorry No Records found
What are the side effects of BenzePrO Creamy Wash?
Sorry No records found
What should I look out for while using BenzePrO Creamy Wash?
BenzePrOTM Creamy Wash is contraindicated in persons with a known hypersensitivity to any of its ingredients.
Do not use if you:
When using this product:
Stop use and ask a doctor if:
What might happen if I take too much BenzePrO Creamy Wash?
If excessive scaling, erythema or edema occurs, the use of this preparation should be discontinued. To hasten resolution of the adverse effects, cool compresses may be used. After symptoms and signs subside, a reduced dosage schedule may be cautiously tried if the reaction is judged to be due to excessive use and not allergenicity.
How should I store and handle BenzePrO Creamy Wash?
BenzePrO™ Creamy Wash is supplied in a 180 g bottle (NDC 42546-017-18).Store at controlled room temperature 20°-25° C (68°-77° F); excursions permitted to 15°-30°C (59°-86°F). Protect from freezing.KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured for:PruGen, Inc. Pharmaceuticals8714 E Vista Bonita DrScottsdale, AZ 85255BenzePrO™ Creamy Wash is supplied in a 180 g bottle (NDC 42546-017-18).Store at controlled room temperature 20°-25° C (68°-77° F); excursions permitted to 15°-30°C (59°-86°F). Protect from freezing.KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured for:PruGen, Inc. Pharmaceuticals8714 E Vista Bonita DrScottsdale, AZ 85255BenzePrO™ Creamy Wash is supplied in a 180 g bottle (NDC 42546-017-18).Store at controlled room temperature 20°-25° C (68°-77° F); excursions permitted to 15°-30°C (59°-86°F). Protect from freezing.KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured for:PruGen, Inc. Pharmaceuticals8714 E Vista Bonita DrScottsdale, AZ 85255BenzePrO™ Creamy Wash is supplied in a 180 g bottle (NDC 42546-017-18).Store at controlled room temperature 20°-25° C (68°-77° F); excursions permitted to 15°-30°C (59°-86°F). Protect from freezing.KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured for:PruGen, Inc. Pharmaceuticals8714 E Vista Bonita DrScottsdale, AZ 85255BenzePrO™ Creamy Wash is supplied in a 180 g bottle (NDC 42546-017-18).Store at controlled room temperature 20°-25° C (68°-77° F); excursions permitted to 15°-30°C (59°-86°F). Protect from freezing.KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured for:PruGen, Inc. Pharmaceuticals8714 E Vista Bonita DrScottsdale, AZ 85255
×
Clinical Information
Chemical Structure
No Image found
Clinical Pharmacology
The mechanism of action of Benzoyl Peroxide is not totally understood but its antibacterial activity against Propionibacterium acnes is thought to be a major mode of action. In addition, patients treated with Benzoyl Peroxide show a reduction in lipids and free fatty acids, and mild desquamation (drying and peeling activity) with simultaneous reduction in comedones and acne lesions. Little is known about the percutaneous penetration, metabolism, and excretion of Benzoyl Peroxide, although it has been shown that Benzoyl Peroxide absorbed by the skin is metabolized to benzoic acid and then excreted as benzoate in the urine. There is no evidence of systemic toxicity caused by Benzoyl Peroxide in humans.
Non-Clinical Toxicology
BenzePrOTM Creamy Wash is contraindicated in persons with a known hypersensitivity to any of its ingredients.
Do not use if you:
When using this product:
Stop use and ask a doctor if:
Combined use of haloperidol and lithium: An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus haloperidol. A causal relationship between these events and the concomitant administration of lithium and haloperidol has not been established; however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.
The possibility of similar adverse interactions with other antipsychotic medication exists.
Lithium may prolong the effects of neuromuscular blocking agents. Therefore, neuromuscular blocking agents should be given with caution to patients receiving lithium.
Caution should be used when lithium and diuretics or angiotensin converting enzyme (ACE) inhibitors are used concomitantly because sodium loss may reduce the renal clearance of lithium and increase serum lithium levels with risk of lithium toxicity. When such combinations are used, the lithium dosage may need to be decreased, and more frequent monitoring of lithium plasma levels is recommended.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS): Lithium levels should be closely monitored when patients initiate or discontinue NSAID use. In some cases, lithium toxicity has resulted from interactions between an NSAID and lithium. Indomethacin and piroxicam have been reported to increase significantly steady-state plasma lithium concentrations. There is also evidence that other non-steroidal anti-inflammatory agents, including the selective cyclooxygenase-2 (COX-2) inhibitors, have the same effect. In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with celecoxib 200 mg BID as compared to subjects receiving lithium alone.
For external use only. If severe irritation develops, discontinue use and institute appropriate therapy. After reaction clears, treatment may often be resumed with less frequent application. These preparations should not be used in or near the eyes or on mucous membranes.
Allergic contact dermatitis and dryness have been reported with topical Benzoyl Peroxide therapy.
×
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Clonazepam Description
Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake.
Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula:
C15H10ClN3O3 M.W. 315.72
×
Tips
Tips
×
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib).
228 major drug interactions (854 brand and generic names)
210 moderate drug interactions (691 brand and generic names)
2 minor drug interactions (4 brand and generic names)
Show all medications in the database that may interact with Imbruvica (ibrutinib).
